CG Oncology’s (CGON) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of CG Oncology (NASDAQ:CGON) in a report issued on Thursday morning, Benzinga reports. Cantor Fitzgerald currently has a $75.00 price target on the stock.

CGON has been the topic of several other reports. HC Wainwright reiterated a buy rating and issued a $75.00 price objective on shares of CG Oncology in a research report on Thursday, April 4th. Morgan Stanley began coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They issued an overweight rating and a $55.00 price target on the stock. Finally, The Goldman Sachs Group initiated coverage on CG Oncology in a research report on Tuesday, February 20th. They set a neutral rating and a $42.00 price objective for the company.

CG Oncology Price Performance

NASDAQ CGON traded down $3.23 during mid-day trading on Thursday, hitting $36.27. The stock had a trading volume of 2,443,166 shares, compared to its average volume of 390,521. The stock has a 50 day moving average price of $39.63. CG Oncology has a 52-week low of $28.55 and a 52-week high of $50.23.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CG Oncology stock. BNP Paribas Financial Markets bought a new stake in CG Oncology, Inc. (NASDAQ:CGON) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 11,198 shares of the company’s stock, valued at approximately $492,000. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.